The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending ranibizumab (Lucentis, Novartis) as a treatment for sight problems caused by macular oedema (NICE)
Diabetes News Service
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending ranibizumab (Lucentis, Novartis) as a treatment for sight problems caused by macular oedema (NICE)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales